MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33949926/
Multiple myeloma (MM) is a common malignant hematological malignancy. Recently, interest has grown in the role of non-coding regions in disease pathogenesis. MicroRNAs (miRNAs) are small non-coding RNAs containing 19-25...
Evaluation of an open-source machine-learning tool to quantify bone marrow plasma cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33952591/
doi: 10.1136/jclinpath-2021-207524. Online ahead of print. 1 Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, Canada [email protected]. 2 Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario,...
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33951891/
DIS3 gene mutations (DIS3mts) occur in roughly 10% of multiple myeloma (MM) patients; furthermore, DIS3 expression could be affected by monosomy 13 or del(13q), which occur in approximately 40% of...
Genetic Predictors of Mortality in Multiple Myeloma | TACG
Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells. The disease is virtually always preceded by an asymptomatic stage named monoclonal gammopathy of undetermined...
-
Mark Fesler4yrThis article is a nice review of genetic abnormalities associated with myeloma, yet much remains to be learned about the mechanisms of progression and varying rates of such complications
Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33910332/
doi: 10.3324/haematol.2020.277152. Online ahead of print. 1 Department of Medicine I, Wilhelminen Cancer Research Institute, Clinic Ottakring, Vienna, Austria; Recipient of a DOC Fellowship of the Austrian Academy of Sciences...
-
Mark Fesler4yrWill be interesting to see if this bench research on myeloma cell lines can be translated into a clinically useful combination strategy at the bedside